Latest news with #Mosquirix
Time of India
2 hours ago
- Business
- Time of India
Bharat Biotech, GSK to slash malaria vax prices to less than $5 per dose by 2028
HYDERABAD: Vaccine maker Bharat Biotech International Ltd and British biopharma giant GSK plc will be slashing the prices of the world's first malaria vaccine – RTS,S or Mosquirix – by over half to less than $5 per dose by 2028 as part of their pledges to Gavi's replenishment process for 2026-2030. Tired of too many ads? go ad free now The proposed price reduction will be driven by process improvements, expanded production capacity, cost- effective manufacturing, and minimal profit margins, they said in a joint statement on Wednesday. The vaccine, developed by GSK, global non-profit PATH and partners, was the first malaria vaccine to be recommended by the World Health Organization (WHO) in 2021. The same year Bharat Biotech entered into a product transfer agreement with them to manufacture the vaccine in India. As part of the pact, GSK will be transferring the technology for the antigen part of the vaccine to Bharat Biotech and has also granted a licence on all rights for the vaccine, with Bharat Biotech taking over the complete manufacturing of the vaccine by 2028 and enabling the price reduction to below $5 per dose. GSK said it has made significant investments to enhance production capacity and efficiency, and to undertake the planned technology transfer to Bharat Biotech. Bharat Biotech, on the other hand, has invested over $200 million in setting up new, higher- output manufacturing facilities, product development and technology transfers. 'These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete,' the joint statement said. Bharat Biotech executive chairman Dr Krishna Ella said the pledge is more than a pricing announcement and is a commitment to global equity, innovation, and collaboration. Tired of too many ads? go ad free now 'By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria.' GSK's chief global health officer Thomas Breuer said his company had partnered with Bharat Biotech in 2021 with a common goal to find a sustainable solution to malaria. 'The GSK team has worked hand in hand with Bharat Biotech to transfer the vaccine manufacturing technology, while simultaneously implementing crucial improvements in manufacturing efficiencies, resulting in today's pledge to the Gavi replenishment,' he said.
&w=3840&q=100)
Business Standard
10 hours ago
- Health
- Business Standard
Bharat Biotech, GSK to slash malaria vaccine price to $5 per dose by 2028
Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to $5 per dose by 2028, more than halving its current cost, they said on Wednesday. The vaccine, Mosquirix or RTS,S, was developed by GSK and the non-profit PATH, and was the first malaria vaccine to get approval from the World Health Organization in 2022. GSK is working on a technology transfer to Bharat, and will continue to supply the adjuvant part of the vaccine to Bharat when the Indian drugmaker fully takes over production of the shot by 2028. A phased reduction in price for the vaccine will begin immediately, GSK said in a statement with Bharat, reaching the target price of $5 by 2028. The price cut was "driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins," the statement read. Malaria kills more than 500,000 people annually, mainly children aged five and under in sub-Saharan Africa, according to WHO estimates. Cases and deaths fell significantly between 2000 and 2015, but progress has since stalled and even reversed, with a particular jump in mortality during the COVID-19 pandemic. Many experts have expressed hope that vaccines can help turn the tide in the fight against the mosquito-borne disease. But price has been an issue, particularly when compared to other tools to prevent malaria like bed nets. GSK has previously said it was committed to supplying up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028, according to a spokesperson. Wednesday's announcement comes as Gavi - a global vaccine group that helps buy childhood vaccines in the world's poorest countries - holds an event in Brussels to raise funding for its work over the next five years, as governments pull back from international aid. GSK and Bharat said the price reduction showed their commitment to Gavi, which has been funding some of the roll-out of the malaria vaccine. Twelve African countries are set to introduce the vaccine in their routine immunisation programmes by the end of this year with Gavi's support. The other approved malaria vaccine, developed by the University of Oxford and the Serum Institute of India, is priced at under $4 a dose.
Time of India
11 hours ago
- Health
- Time of India
Bharat Biotech, GSK to halve price of malaria vaccine by 2028
Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to $5 per dose by 2028, more than halving its current cost, they said on Wednesday. The vaccine, Mosquirix or RTS,S, was developed by GSK and the non-profit PATH, and was the first malaria vaccine to get approval from the World Health Organization in 2022. GSK is working on a technology transfer to Bharat, and will continue to supply the adjuvant part of the vaccine to Bharat when the Indian drugmaker fully takes over production of the shot by 2028. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villa For Sale in Dubai Might Surprise You Villas in Dubai | Search ads Learn More Undo A phased reduction in price for the vaccine will begin immediately, GSK said in a statement with Bharat, reaching the target price of $5 by 2028. The price cut was "driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins," the statement read. Live Events Malaria kills more than 500,000 people annually, mainly children aged five and under in sub-Saharan Africa, according to WHO estimates. Cases and deaths fell significantly between 2000 and 2015, but progress has since stalled and even reversed, with a particular jump in mortality during the COVID-19 pandemic. Many experts have expressed hope that vaccines can help turn the tide in the fight against the mosquito-borne disease. But price has been an issue, particularly when compared to other tools to prevent malaria like bed nets. GSK has previously said it was committed to supplying up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028, according to a spokesperson. Wednesday's announcement comes as Gavi - a global vaccine group that helps buy childhood vaccines in the world's poorest countries - holds an event in Brussels to raise funding for its work over the next five years, as governments pull back from international aid. GSK and Bharat said the price reduction showed their commitment to Gavi, which has been funding some of the roll-out of the malaria vaccine. Twelve African countries are set to introduce the vaccine in their routine immunisation programmes by the end of this year with Gavi's support. The other approved malaria vaccine, developed by the University of Oxford and the Serum Institute of India, is priced at under $4 a dose.
